Sibeprenlimab decreases 24-hour UACR in IgA nephropathy: ENVISION Trial Results.

Published Date: 05 Nov 2023

ASN Kidney Week 2023 saw the presentation of the ENVISION trial results, which offer the most recent information on the role of sibeprenlimab in the treatment of IgA nephropathy while the nephrology community waits for the outcomes of the trial's ongoing phase 3 development.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot